Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.42 |
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999113 | 0.84 | MEN1 (0.48) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL5075925 | 0.83 | NR3C1 (0.54) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL6900013 | 0.81 | MEN1 (0.34) | MAPTIMPDH2MEN1KMT2ARXFP1 | |
| SCHEMBL6556615 | 0.79 | MAPT (0.54) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL4000712 | 0.78 | MAPT (0.55) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL6554195 | 0.78 | NR3C1 (0.53) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL5077893 | 0.77 | NR3C1 (0.48) | NR3C1PGRNR3C2 | |
| SCHEMBL6585718 | 0.75 | MAPT (0.53) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL6586100 | 0.75 | MAPT (0.53) | MAPTKDM4EPOLBNPSR1IMPDH2 | |
| SCHEMBL6587487 | 0.74 | MAPT (0.52) | MAPTKDM4EPOLBNPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| EP-1482925-B1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL]-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232824-A1 | Non-steroidal progesting | PGR, NR5A1, GPER1 | MAPT 4845/4885KDM4E 3269/4885POLB 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.